Skip to main content
Top
Published in: BMC Infectious Diseases 1/2016

Open Access 01-12-2016 | Research article

Quality assurance of human papillomavirus (HPV) testing in the implementation of HPV primary screening in Norway: an inter-laboratory reproducibility study

Authors: Birgit Engesæter, Bianca van Diermen Hidle, Mona Hansen, Pia Moltu, Kjersti Mangseth Staby, Siri Borchgrevink-Persen, Olav K. Vintermyr, Stefan Lönnberg, Mari Nygård, Emiel A. M. Janssen, Philip E. Castle, Irene Kraus Christiansen

Published in: BMC Infectious Diseases | Issue 1/2016

Login to get access

Abstract

Background

Human papillomavirus (HPV) testing as primary screening for cervical cancer is currently being implemented in Norway in a randomized controlled fashion, involving three laboratories. As part of the quality assurance programme of the implementation, an evaluation of the inter-laboratory reproducibility of the HPV test was initiated, to ensure satisfactory HPV test reliability in all three laboratories.

Methods

The HPV test used is the cobas 4800 HPV Test, detecting 14 high-risk types with individual HPV genotype results for HPV16 and HPV18. In addition to the three laboratories involved in the implementation, the Norwegian HPV reference laboratory was included as a fourth comparative laboratory. A stratified sample of 500 cervical liquid based cytology (LBC) samples was used in the evaluation, with an aim towards a high-risk HPV positivity of ~25%. Samples were collected at one laboratory, anonymized, aliquoted, and distributed to the other laboratories.

Results

Comparison of the test results of all four laboratories revealed a 95.6% agreement, an 86.3% positive agreement and a kappa value of 0.94 (95% CI 0.92–0.97). For negative cytology specimens, there was a 95.8% overall agreement, a 67.4% positive agreement, and a kappa value of 0.88 (95% CI 0.80–0.93). For abnormal cytology specimens, there was a 95.8% overall agreement, a 95.5% positive agreement, and a kappa value of 0.86 (95% CI 0.71–0.97).

Conclusions

The study showed a high inter-laboratory reproducibility of HPV testing, implying satisfactory user performance and reliability in the laboratories involved in the implementation project. This is important knowledge and we recommend similar studies always to be performed prior to the introduction of new screening routines.
Appendix
Available only for authorised users
Literature
1.
go back to reference Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, Koliopoulos G, Naucler P, Sankaranarayanan R, Peto J. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30 Suppl 5:F88–99.CrossRefPubMed Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, Koliopoulos G, Naucler P, Sankaranarayanan R, Peto J. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30 Suppl 5:F88–99.CrossRefPubMed
2.
go back to reference Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11(3):249–57.CrossRefPubMed Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11(3):249–57.CrossRefPubMed
3.
go back to reference Anttila A, Arbyn M, De Vuyst H, Dillner J, Dillner L, Franceschi S, Patnik J, Ronco G, Segnan N, Suinio E, et al. European guidelines for quality assurance in cervical cancer screening. Supplements. 2nd ed. Luxembourg: Publication Office of the European Union; 2015. Anttila A, Arbyn M, De Vuyst H, Dillner J, Dillner L, Franceschi S, Patnik J, Ronco G, Segnan N, Suinio E, et al. European guidelines for quality assurance in cervical cancer screening. Supplements. 2nd ed. Luxembourg: Publication Office of the European Union; 2015.
4.
go back to reference Stoler MH, Schiffman M, Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study G. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA. 2001;285(11):1500–5.CrossRefPubMed Stoler MH, Schiffman M, Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study G. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA. 2001;285(11):1500–5.CrossRefPubMed
5.
go back to reference Flack VF, Lachenbruch PA, Schouten HJA. Sample size determinations for the two rater kappa statistic. Psychometrika. 1988;53(3):321–5.CrossRef Flack VF, Lachenbruch PA, Schouten HJA. Sample size determinations for the two rater kappa statistic. Psychometrika. 1988;53(3):321–5.CrossRef
6.
go back to reference Wright TC Jr, Stoler MH, Behrens CM, Apple R, Derion T, Wright TL. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol. 2012;206(1):46 e41-46 e11 Wright TC Jr, Stoler MH, Behrens CM, Apple R, Derion T, Wright TL. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol. 2012;206(1):46 e41-46 e11
7.
go back to reference Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, Arbyn M, Bosch FX, Cuzick J, Dillner J, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009;124(3):516–20.CrossRefPubMedPubMedCentral Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, Arbyn M, Bosch FX, Cuzick J, Dillner J, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009;124(3):516–20.CrossRefPubMedPubMedCentral
8.
go back to reference Rao A, Young S, Erlich H, Boyle S, Krevolin M, Sun R, Apple R, Behrens C. Development and characterization of the cobas human papillomavirus test. J Clin Microbiol. 2013;51(5):1478–84.CrossRefPubMedPubMedCentral Rao A, Young S, Erlich H, Boyle S, Krevolin M, Sun R, Apple R, Behrens C. Development and characterization of the cobas human papillomavirus test. J Clin Microbiol. 2013;51(5):1478–84.CrossRefPubMedPubMedCentral
9.
go back to reference Schiffman M, Boyle S, Raine-Bennett T, Katki HA, Gage JC, Wentzensen N, Kornegay JR, Apple R, Aldrich C, Erlich HA, et al. The role of human papillomavirus genotyping in cervical cancer screening: a large-scale evaluation of the cobas HPV test. Cancer Epidemiol Biomarkers Prev. 2015;24(9):1304–10.CrossRefPubMedPubMedCentral Schiffman M, Boyle S, Raine-Bennett T, Katki HA, Gage JC, Wentzensen N, Kornegay JR, Apple R, Aldrich C, Erlich HA, et al. The role of human papillomavirus genotyping in cervical cancer screening: a large-scale evaluation of the cobas HPV test. Cancer Epidemiol Biomarkers Prev. 2015;24(9):1304–10.CrossRefPubMedPubMedCentral
10.
go back to reference Eklund C, Forslund O, Wallin KL, Dillner J. Global improvement in genotyping of human papillomavirus DNA: the 2011 HPV LabNet International Proficiency Study. J Clin Microbiol. 2014;52(2):449–59.CrossRefPubMedPubMedCentral Eklund C, Forslund O, Wallin KL, Dillner J. Global improvement in genotyping of human papillomavirus DNA: the 2011 HPV LabNet International Proficiency Study. J Clin Microbiol. 2014;52(2):449–59.CrossRefPubMedPubMedCentral
11.
go back to reference Carozzi FM, Del Mistro A, Cuschieri K, Frayle H, Sani C, Burroni E. HPV testing for primary cervical screening: laboratory issues and evolving requirements for robust quality assurance. J Clin Virol. 2016;76 Suppl 1:S22–8.CrossRefPubMed Carozzi FM, Del Mistro A, Cuschieri K, Frayle H, Sani C, Burroni E. HPV testing for primary cervical screening: laboratory issues and evolving requirements for robust quality assurance. J Clin Virol. 2016;76 Suppl 1:S22–8.CrossRefPubMed
Metadata
Title
Quality assurance of human papillomavirus (HPV) testing in the implementation of HPV primary screening in Norway: an inter-laboratory reproducibility study
Authors
Birgit Engesæter
Bianca van Diermen Hidle
Mona Hansen
Pia Moltu
Kjersti Mangseth Staby
Siri Borchgrevink-Persen
Olav K. Vintermyr
Stefan Lönnberg
Mari Nygård
Emiel A. M. Janssen
Philip E. Castle
Irene Kraus Christiansen
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2016
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-016-2028-7

Other articles of this Issue 1/2016

BMC Infectious Diseases 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.